|
Morpheus Aerospace Case Study
Closely held and
family controlled businesses that excel at the
seven factors that characterize successful
wealth creating family enterprises, as discussed
in Highland Global’s The Seven Deadly Sins of
Business Valuation: Closely Held and Family
Controlled Businesses, typically are able to
lower the firm’s cost of capital as compared to
those firms that have yet to master the seven
factors of successful transgenerational wealth
creating enterprises. While this lower cost of
capital may serve to increase the value of the
company, patient capital arising from mastery of
the seven factors, particularly good relations
between management and shareholders, may change
the investment options for the firm. This in
turn may further enable the company to create
long-term wealth by investing in value-adding
projects that would otherwise be rejected if the
company’s cost of capital were higher.
Morpheus
Aerospace, Inc. is currently assessing various
investment options relating to expansion of its
business. The investment options include the
following opportunities:
·
Acquisition of a
small aircraft manufacturing firm in Canada—This
acquisition is expected to cost roughly $30
million and would generate additional net cash
flow to invested capital of roughly $3 million
per year. The acquisition would also create
additional synergies estimated at roughly $1.5
million per year.
·
Expansion of the
Company’s operations in Latin America—The
expansion would cost an estimated $15 million
for additional facilities and infrastructure.
The incremental net cash flow to invested
capital is estimated at $1.5 million but could
be substantially higher should the company be
able to expand sales throughout South America
and the Caribbean as a result of its investment
in the region.
·
Acquisition of a
publicly traded aerospace company, Royal
Aerospace, in Great Britain—Royal
Aerospace is currently being courted by both
Morpheus Aerospace, a closely held and family
controlled business, and Troilis International,
a publicly traded company listed in London,
as a potential acquisition target. Royal
Aerospace currently has net cash flow to
invested capital of £0 and is expected to
continue to generate no cash flow to invested
capital in the future. Troilis International
has offered £12 million for Royal Aerospace and
seeks to achieve annual synergies of £2
million. Troilis International’s weighted
average cost of capital is 12%. Morpheus
Aerospace has offered £15 million for Royal
Aerospace with hopes of achieving annual
synergies of £2 million and collateral benefits
associated with expansion into the British
market.
The following
table provides a comparison of each of the three
investment opportunities and the expected
return.
|
TABLE 1 |
|
|
|
|
|
|
Morpheus Aerospace, Inc. Investment
Option Analysis |
|
|
|
|
Investment Opportunity |
Cost or |
Incremental |
Estimated Annual |
Total |
Return on |
|
|
Investment |
Annual NCFIV |
Synergies |
Expected Return |
Investment |
|
Acquisition of Canadian firm |
$30,000,000 |
$3,000,000 |
$1,500,000 |
$4,500,000 |
15.00% |
|
Expansion in Latin America |
$15,000,000 |
$1,250,000 |
$0 |
$1,250,000 |
8.33% |
|
Acquisition of Royal Aerospace |
£15,000,000 |
£0 |
£2,000,000 |
£2,000,000 |
13.33% |
Consider a situation where Morpheus Aerospace
excels at the seven characteristics of
successful transgenerational wealth creating
enterprises. In addition, relations between the
executive management, the Board of Directors,
and the shareholders are highly favorable. The
patient capital return requirements are lowered
by a low Specific Company Risk Premium and the
absence of any additional Family Business Risk
Premium. As a result, Morpheus Aerospace’
weighted average cost of capital is estimated at
10%.
With a 10%
hurdle rate, Morpheus Aerospace’ investment
decision would be to invest in the acquisition
of the Canadian firm, as this provides a return
in excess of the required rate and, thus,
creates value for the Company.
In the absence
of any additional synergies or collateral
benefits, the Company would reject the expansion
in Latin America, as the return on the
investment of 8.3% falls short of the Company’s
hurdle rate of 10%. Based on these assumptions,
an investment in this project would ultimately
destroy value for the Company. However, the
Company may still choose to undertake this
project if there is a probability that the
collateral benefits of the expansion would
increase the return on the investment to a 10%
return on investment or greater.
Morpheus
Aerospace would also create value for
shareholders by investing in the acquisition of
Royal Aerospace, as the 13.33% return is higher
than the Company’s weighted average cost of
capital (ignoring the impact of currency
exchange). Suppose, however, that Morpheus
Aerospace and Troilis International engage in a
bidding war for Royal Aerospace. Troilis
International increases their bid to £16.667
million. As a result, Troilis International’s
expected return on the investment is 12%,
exactly equal to its weighted average cost of
capital. This indicates that at the offered
price the transaction would, theoretically,
neither add value nor destroy value for Troilis’
shareholders. Morpheus Aerospace, however,
through a skillful use of leverage in its
capital structure coupled with the patient
capital associated with good relations with the
shareholders, has managed to lower its weighted
average cost of capital to 10%. Therefore,
Morpheus Aerospace increases its offer for Royal
Aerospace to £17.5 million, which still provides
a return on the investment of 11.43%--higher
than the Company’s hurdle rate, suggesting that
the investment will create value for the
shareholders. In theory, Morpheus Aerospace
could have increased the bid for the Royal
Aerospace to a high of £20 million, which would
have given the project a net present value of
zero—the present value of the cash flows would
have equaled the initial investment—and a return
equal to that of the Company’s hurdle rate of
10%.
Now, consider
the case where Morpheus Aerospace has a great
deal of dissention among the shareholders and
relations between management and the family
members are acrimonious. As a result of the
increased risk associated with the family risk
factors, at which the Company fails to excel,
the cost of equity capital increases, which
increases the Company’s weighted average cost of
capital to 15%. As a result, Morpheus Aerospace
would forego the investment in the acquisition
of Royal Aerospace at £15 million as well as the
expansion in Latin America, both of which have
returns that are significantly below the
increased hurdle rate of 15%. With respect to
the acquisition of the Canadian firm, Morpheus
Aerospace would likely realize no increase in
value from that investment as the return is
equal to the firm’s hurdle rate of 15%; thus,
the net present value of the project is zero.
This
should illustrate clearly how good shareholder
relations and the ability of a company to excel
at the factors that characterize a successful
transgenerational wealth creating enterprise may
ultimately impact the investment options for the
company. Demand capital could adversely impact
the ability of the company to invest in
value-adding projects and thereby hinder
long-term wealth creation for the shareholders.
Patient capital would likely contribute to a
healthy family enterprise and may expand the
possible investment options for the company.
This in turn may foster growth, stability, and
long-term wealth creation through investment in
projects that add value to the enterprise.
|